Pediatr Infect Vaccine.  2018 Apr;25(1):35-44. 10.14776/piv.2018.25.1.35.

Immunogenicity and Safety of Inactivated Influenza Vaccine in Healthy Korean Children and Adolescent

• Ri S
• Kim MJ
• Kim YK

• KMID: 2438752
• DOI: http://doi.org/10.14776/piv.2018.25.1.35

Abstract

PURPOSE
This study aimed to evaluate the immunogenicity and safety of a trivalent inactivated influenza vaccine (TIV) among healthy Korean children and adolescents.
METHODS
From October to December 2008, 65 healthy patients aged 6 months to 18 years who visited Korea University Ansan Hospital for influenza vaccination were enrolled in this study. We measured the hemagglutinin inhibition antibody titers at baseline and 30 days after vaccinating enrollees with split influenza vaccine and calculated the seroprotection rates, geometric mean titers, and seroconversion rates. Local and systemic adverse events were assessed after vaccination.
RESULTS
The seroprotection rates against all three viral strains (A/H1N1, A/H3N2, B) were 87.7%, 89.2%, and 89.2% (≥70%), respectively; seroconversion rates were 44.6%, 73.8%, and 63.1% (≥40%), respectively; and seroconversion factors were 4.5, 8.4, and 10.5 (>2.5), respectively. The TIV immunogenicity was acceptable according to the CPMP (Committee for Proprietary Medicinal Products) criteria. Although 48 patients (73.8%) reported one or more adverse events, no severe adverse events such as anaphylaxis and convulsion were observed. Forty-two patients (64.6%) reported a local skin reaction, including redness (29.2%), pain (43.1%), or swelling (41.5%) of the injected site, and 26 (40.0%) reported a systemic reaction: fatigue (23.1%), myalgia (20.0%), headache (10.8%), arthralgia (10.8%), chills (9.2%), or fever (7.7%).
CONCLUSIONS
This study shows that the immunogenicity of the TIV vaccine is acceptable. As there were no serious adverse events aside from local reactions and mild systemic reactions, this vaccine can be safely used among healthy Korean children and adolescents.

Keyword

Influenza vaccines; mmunogenicity, vaccine; Safety

MeSH Terms

Adolescent*
Anaphylaxis
Arthralgia
Child*
Chills
Fatigue
Fever
Gyeonggi-do
Headache
Hemagglutinins
Humans
Influenza Vaccines*
Influenza, Human*
Korea
Myalgia
Seizures
Seroconversion
Skin
Vaccination
Hemagglutinins
Influenza Vaccines

Reference

References

1. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003; 289:179–86.

2. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004; 292:1333–40.

3. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009; 58(RR-8):1–52.

4. Cheong HJ, Song JY, Park JW, Yeon JE, Byun KS, Lee CH, et al. Humoral and cellular immune responses to influenza vaccine in patients with advanced cirrhosis. Vaccine. 2006; 24:2417–22.

5. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008; 57(RR-7):1–60.

6. Organization for Economic Cooperation and Development (OECD). 2015 Influenza vaccination rates [Internet]. Paris: OECD;c2018. [cited 2018 Mar 17]. Available from:. https://data.oecd.org.

7. Korean Statistical Information Service. 2015 Influenza vaccination rate for children and adolescents [Internet]. Daejeon: Statistics Korea;2015. [cited 2018 Mar 17]. Available from:. http://kosis.kr.

8. Kim YK, Eun BW, Lee TJ, Lee J, Kim KH, Kim DH, et al. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV) in South Korean children and adolescents: a randomized, double-blind, multicenter, phase 3 clinical trial. Open Forum Infect Dis. 2016; 3(Suppl 1):S201.

9. Cintra OA, Rey LC. Safety, immunogenicity and efficacy of influenza vaccine in children. J Pediatr (Rio J). 2006; 82(3 Suppl):S83–90.

10. Wright PF. The use of inactivated influenza vaccine in children. Semin Pediatr Infect Dis. 2006; 17:200–5.

11. Han SB, Rhim JW, Shin HJ, Lee SY, Kim HH, Kim JH, et al. Immunogenicity and safety assessment of a trivalent, inactivated split influenza vaccine in Korean children: Double-blind, randomized, active-controlled multicenter phase III clinical trial. Hum Vaccin Immunother. 2015; 11:1094–102.

12. Committee for Medicinal Products for Human Use. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application [Internet]. London: European Medicines Agency;2008. [cited 2018 Mar 17]. Available from:. http://www.ema. europa.eu.

13. Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines [Internet]. London: European Agency for the Evaluation of Medicinal Products;1997. [cited 2018 Mar 17]. Available from:. http://www.ema.europa.eu.

14. Walter EB, Rajagopal S, Zhu Y, Neuzil KM, Fairchok MP, Englund JA. Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? Vaccine. 2010; 28:4376–83.

15. Seidman JC, Richard SA, Viboud C, Miller MA. Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza Other Respir Viruses. 2012; 6:52–62.

16. Langley JM, Vanderkooi OG, Garfield HA, Hebert J, Chandrasekaran V, Jain VK, et al. Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6–35 months: a randomized, controlled trial. J Pediatric Infect Dis Soc. 2012; 1:55–63.

17. Yang P, Thompson MG, Ma C, Shi W, Wu S, Zhang D, et al. Influenza vaccine effectiveness against medically-attended influenza illness during the 2012–2013 season in Beijing, China. Vaccine. 2014; 32:5285–9.

18. Song JY, Ha SH, Kee SY, Jeong HW, Cheong HJ, Kim WJ. Debate on annual influenza vaccination in healthcare workers for the same subtype under the vaccine shortage. J Clin Virol. 2007; 38:149–52.

19. Ahout I, Ferwerda G, de Groot R. Influenza vaccination in kids, are you kidding me? J Infect. 2014; 68(Suppl 1):S100–7.

20. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpaa R, Ziegler T, Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis. 2011; 11:23–9.

21. Blyth CC, Jacoby P, Effler PV, Kelly H, Smith DW, Robins C, et al. Effectiveness of trivalent flu vaccine in healthy young children. Pediatrics. 2014; 133:e1218–25.

22. Kee SY, Lee JS, Cheong HJ, Chun BC, Song JY, Choi WS, et al. Influenza vaccine coverage rates and perceptions on vaccination in South Korea. J Infect. 2007; 55:273–81.

23. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demi cheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2008; 2:CD004879.

24. Neuzil KM, Edwards KM. Influenza vaccines in children. Semin Pediatr Infect Dis. 2002; 13:174–81.

25. McMahon AW, Iskander J, Haber P, Chang S, Woo EJ, Braun MM, et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990–2003. Pediatrics. 2005; 115:453–60.

26. Kanra G, Marchisio P, Feiterna-Sperling C, Gaedicke G, Lazar H, Durrer P, et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J. 2004; 23:300–6.

27. Jo YM, Ki SY, Song JY, Choi WS, Kim JY, Seo YB, et al. Immunogenicity and safety of half dose intradermal injection compared to full dose intramuscular injection of influenza vaccine in healthy adults. Infect Chemother. 2006; 38:259–65.

28. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gitt-leson C, Bennet J, et al. Response to a monovalent 2009 in fluenza A (H1N1) vaccine. N Engl J Med. 2009; 361:2405–13.

29. al-Mazrou A, Scheifele DW, Soong T, Bjornson G. Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel. CMAJ. 1991; 145:213–8.

30. Kim YK, Eun BW, Kim NH, Kang EK, Lee BS, Kim DH, et al. Comparison of immunogenicity and reactogenicity of split versus subunit influenza vaccine in Korean children aged 6–35 months. Scand J Infect Dis. 2013; 45:460–8.

31. Masurel N, Ophof P, de Jong P. Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus. J Hyg (Lond). 1981; 87:201–9.